Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Achieve Life Sciences, Inc. (ACHV)
USD6.14
+0.04 (+0.66%)
CA NASDAQ Healthcare Biotechnology
Address
1040 West Georgia Street V6E 4H1
Vancouver, BC, CA
Vancouver, BC, CA
CEO
Richard A. Stewart
Website
achievelifesciences.com
IPO
1995-10-12
CIK 949858 ISIN US0044685008
Description
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
News Sentiment (7d)
Based on only 2 articles — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| OncoGenex Pharmaceuticals | OGXI | 2017-03-27 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD6.14
+0.04 (+0.66%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
2.26
Float Shares
46.58M
Free Float %
87.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +7.16% | +24.53% | +71.63% | +45.04% | +26.91% | +20.52% | +141.53% | -27.13% | -38.25% | -99.67% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (6 ratings, all time)
Buy
Price Targets & DCF
Current price
6.14
Low
13.00
+111.7%
Consensus
13.00
+111.7%
Median
13.00
+111.7%
High
13.00
+111.7%
DCF (Unlevered)
0.12
-98.1%
DCF (Levered)
0.14
-97.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 6 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
13.00
+111.7%
|
| Last Quarter | 1 |
13.00
+111.7%
|
| Last Year | 1 |
13.00
+111.7%
|
| All Time | 3 |
7.50
+22.1%
|
Quality scores
Altman Z-Score
-6.92
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-0.8% Q1'26: +48.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-79,536.2% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+35.9% Q1'26: +53.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.27×
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 1996 actual |
Dec 1997 actual |
Dec 1999 actual |
Dec 2002 actual |
Dec 2003 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 5 EPS Ana. |
Dec 2027 6 Rev. Ana. 5 EPS Ana. |
Dec 2028 5 Rev. Ana. 5 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
16.60M
est: 59.98M (-72.3%)
|
18.90M
est: 30.45M (-37.9%)
|
12.10M
est: 64.73M (-81.3%)
|
25.0K
est: 299.2K (-91.6%)
|
25.0K
est: 182.3K (-86.3%)
|
18.16M
est: 19.78M (-8.2%)
|
5.06M
est: 4.78M (+5.9%)
|
—
est: 4.50M (-100.0%)
|
—
est: 40.0K (-100.0%)
|
—
est: 100.0K (-100.0%)
|
—
|
—
est: 16.42M (-100.0%)
|
4.50M
4.25M – 4.75M
-72.6% YoY
|
40.80M
23.89M – 57.70M
+806.6% YoY
|
144.44M
144.43M – 144.45M
+254.0% YoY
|
302.54M
215.22M – 389.85M
+109.5% YoY
|
434.75M
309.28M – 560.22M
+43.7% YoY
|
| EBITDA |
2.10M
est: 19.40M (-89.2%)
|
700.0K
est: 3.59M (-80.5%)
|
589.5K
est: 37.89M (-98.4%)
|
-11.59M
est: -11.33M (-2.4%)
|
-10.26M
est: -12.18M (+15.8%)
|
-16.56M
|
-19.94M
|
-13.35M
|
-32.90M
|
-40.33M
|
-37.42M
|
-54.65M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
1.60M
est: 13.93M (-88.5%)
|
100.0K
est: -625.7K (+116.0%)
|
-10.5K
est: 8.66M (-100.1%)
|
-12.17M
est: -12.27M (+0.8%)
|
-10.64M
est: -12.72M (+16.4%)
|
-18.75M
|
-20.13M
|
-13.63M
|
-33.15M
|
-40.56M
|
-37.65M
|
-54.88M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
1.70M
est: 15.12M (-88.8%)
|
1.00M
est: 1.09M (-8.5%)
|
400.0K
est: 36.12M (-98.9%)
|
-11.64M
est: -11.70M (+0.6%)
|
-10.47M
est: -12.51M (+16.3%)
|
-16.80M
est: -63.85B (+100.0%)
|
-20.13M
est: -59.97B (+100.0%)
|
-10.58M
est: -62.09B (+100.0%)
|
-33.15M
est: -125.72M (+73.6%)
|
-42.35M
est: -128.93M (+67.2%)
|
-39.83M
est: -38.83M (-2.6%)
|
-54.65M
est: -54.65M (+0.0%)
|
-54.98M
-57.45M – -52.52M
-0.6% YoY
|
-41.09M
-53.92M – -28.26M
+25.3% YoY
|
18.45M
-13.08M – 59.72M
+144.9% YoY
|
72.59M
45.35M – 99.82M
+293.3% YoY
|
128.28M
80.15M – 176.40M
+76.7% YoY
|
| SGA |
3.80M
est: 11.82M (-67.9%)
|
7.20M
est: 12.31M (-41.5%)
|
6.50M
est: 16.91M (-61.6%)
|
3.24M
|
3.01M
|
11.81M
|
8.93M
|
3.53M
|
9.13M
|
10.72M
|
16.25M
|
31.87M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
7,906.98
est: 48.02 (+16,367.7%)
|
4,608.29
est: -74.55 (+6,281.5%)
|
1,914.85
est: -160.93 (+1,289.9%)
|
-33,726.96
est: -106.70 (-31,509.1%)
|
-23,106.18
est: -115.50 (-19,905.4%)
|
-1,413.63
est: -1,991.00 (+29.0%)
|
-1,478.66
est: -1,870.00 (+20.9%)
|
-441.47
est: -1,936.00 (+77.2%)
|
-4.05
est: -3.92 (-3.3%)
|
-3.95
est: -4.07 (+2.8%)
|
-1.24
est: -1.22 (-1.5%)
|
-1.25
est: -1.28 (+2.0%)
|
-1.26
-1.32 – -1.20
+1.2% YoY
|
-0.95
-1.24 – -0.65
+24.9% YoY
|
0.20
-0.30 – 1.37
+121.3% YoY
|
1.67
1.04 – 2.29
+724.3% YoY
|
2.94
1.84 – 4.05
+76.7% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-16 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-37.55M
OE per share TTM
-3.57
Owner's Yield
-12.61%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
21.4%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
16
Total invested
7.75M
Insider transactions (90d)
4
Beneficial owners (>5%)
32
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ( | 21.67M | 9.90% | — | 2.17M | — | 2.17M | IN | United States of America | 2024-02-27 | ↗ |
| 2 | John Fichthorn | 3.59M | 19.99% | — | — | 55.0K | 3.54M | IN | Delaware | 2023-04-18 | ↗ |
| 3 | Dialectic Capital Management, LP | 3.54M | 19.68% | — | — | — | 3.54M | PN | Delaware | 2023-04-18 | ↗ |
| 4 | Dialectic LS Manager LLC | 3.54M | 19.68% | — | — | — | 3.54M | OO | Delaware | 2023-04-18 | ↗ |
| 5 | Dialectic Life Sciences SPV LLC | 3.54M | 19.68% | — | — | — | 3.54M | OO | Delaware | 2023-04-18 | ↗ |
| 6 | Dialectic Partners, LLC | 3.54M | 19.68% | — | — | — | 3.54M | OO | Delaware | 2023-04-18 | ↗ |
| 7 | Leen Kawas | 2.33M | 6.81% | 2.24M | 98.9K | 2.24M | — | IN | Delaware | 2024-05-17 | ↗ |
| 8 | Propel Bio Management LLC | 2.33M | 6.81% | 2.24M | 98.9K | 2.24M | — | IA | Delaware | 2024-05-17 | ↗ |
| 9 | Propel Bio Partners LLC | 2.33M | 6.81% | 2.24M | 98.9K | 2.24M | — | OO | Delaware | 2024-05-17 | ↗ |
| 10 | Richard Kayne | 2.33M | 6.81% | 2.24M | 98.9K | 2.24M | — | IN | Delaware | 2024-05-17 | ↗ |
| 11 | (1) BlackRock, Inc. | 2.07M | 6.00% | 2.05M | — | 2.07M | — | HC | Delaware | 2024-10-25 | ↗ |
| 12 | SVB Financial Group | 1.71M | 8.70% | 853.4K | 853.4K | 853.4K | 853.4K | IA, HC, CO | Delaware | 2022-11-22 | ↗ |
| 13 | Parker Quillen | 1.37M | 7.64% | — | 1.37M | — | 1.37M | IN | USA | 2022-11-28 | ↗ |
| 14 | Contrarian Achieve GP LLC | 1.32M | 7.37% | — | 1.32M | — | 1.32M | IA | USA | 2022-11-28 | ↗ |
| 15 | Contrarian Achieve SPV LP | 1.32M | 7.37% | — | 1.32M | — | 1.32M | IV | USA | 2022-11-28 | ↗ |
| 16 | John Francis | 594.3K | 6.30% | 22.2K | 572.1K | 22.2K | — | HC, IN | United States | 2022-02-14 | ↗ |
| 17 | Catalysis Partners, LLC | 560.1K | 5.90% | — | 560.1K | — | — | PN | Delaware | 2022-02-14 | ↗ |
| 18 | Francis Capital Management, LLC | 560.1K | 5.90% | — | 560.1K | — | — | IA, HC, OO | California | 2022-02-14 | ↗ |
| 19 | SVB Innovation Credit Fund VIII, L.P. | 426.7K | 2.30% | — | 426.7K | — | 426.7K | PN | Delaware | 2022-11-22 | ↗ |
| 20 | SVB Innovation Credit Partners VIII, LLC | 426.7K | 2.30% | — | 426.7K | — | 426.7K | OO | Delaware | 2022-11-22 | ↗ |
| 21 | VIII-A, | 426.7K | 2.30% | — | 426.7K | — | 426.7K | OO | Delaware | 2022-11-22 | ↗ |
| 22 | Innovation Credit Fund VIII-A, L.P. | 401.5K | 4.10% | — | 401.5K | — | — | PN | Delaware | 2021-12-29 | ↗ |
| 23 | SVB Innovation Credit Partners VIII-A, LLC | 401.5K | 4.10% | — | 401.5K | — | — | OO | Delaware | 2021-12-29 | ↗ |
| 24 | s: Globis Capital Partners, L.P. | 253.6K | 4.40% | — | 253.6K | — | 253.6K | PN | Delaware | 2021-02-12 | ↗ |
| 25 | CVI Investments, Inc. | 227.1K | 3.70% | — | 227.1K | — | 227.1K | CO | — | 2021-02-16 | ↗ |
| 26 | Heights Capital Management, Inc. | 227.1K | 3.70% | — | — | — | 227.1K | CO | — | 2021-02-16 | ↗ |
| 27 | Kamen | 83.3K | 1.42% | — | 83.3K | — | 83.3K | HC | States of America | 2021-02-17 | ↗ |
| 28 | Vida Investments, LLC | 83.3K | 1.42% | — | 83.3K | — | 83.3K | IA | Delaware | 2021-02-17 | ↗ |
| 29 | Vida Master Fund, Ltd. | 65.0K | 1.11% | — | 65.0K | — | 65.0K | OO | Islands | 2021-02-17 | ↗ |
| 30 | Contrarian Alpha GP LLC | 49.0K | 3.71% | — | 49.0K | — | 49.0K | IA | USA | 2022-11-28 | ↗ |
| 31 | Contrarian Alpha Management LLC | 49.0K | 3.71% | — | 49.0K | — | 49.0K | IA | USA | 2022-11-28 | ↗ |
| 32 | Contrarian Alpha, LP | 49.0K | 3.71% | — | 49.0K | — | 49.0K | IV | USA | 2022-11-28 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
16
-67 vs prev Q
New positions
4
Closed positions
67
Increased
8
Reduced
0
Put/Call ratio
0.00
Calls held
133.3K
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | FRANKLIN RESOURCES INC | 4.37M +4.3M (+18,747.4%) | 21.71M +21.7M (+55,990.5%) | 12.60% +12.530 pp | 0.01% +0.005 pp | USD4.96 +0.2% | 8 qtrs — |
| 2 | PROPEL BIO MANAGEMENT, LLC | 3.79M +— (+0.0%) | 18.82M +6.9M (+57.8%) | 10.92% +0.000 pp | 16.07% +4.127 pp | USD3.18 +56.3% | 8 qtrs — |
| 3 | VANGUARD GROUP INC | 2.47M +12.5K (+0.5%) | 12.30M +4.5M (+58.6%) | 7.13% +0.036 pp | 0.00% +0.000 pp | USD4.84 +2.7% | 22 qtrs — |
| 4 | MILLENNIUM MANAGEMENT LLC | 1.36M +1.1M (+472.3%) | 6.75M +6.0M (+802.9%) | 3.92% +3.234 pp | 0.00% +0.003 pp | USD4.50 +10.4% | 4 qtrs — |
| 5 | SIMPLIFY ASSET MANAGEMENT INC. | 1.18M +— (+0.0%) | 5.89M +2.2M (+57.8%) | 3.42% +0.000 pp | 0.10% +0.027 pp | USD2.69 +84.8% | 8 qtrs — |
| 6 | MARSHALL WACE, LLP | 1.02M +244.4K (+31.5%) | 5.07M +2.6M (+107.5%) | 2.94% +0.705 pp | 0.00% +0.002 pp | USD3.59 +38.4% | 2 qtrs — |
| 7 | TWO SIGMA INVESTMENTS, LP | 748.6K +309.6K (+70.5%) | 3.72M +2.3M (+169.0%) | 2.16% +0.893 pp | 0.01% +0.003 pp | USD3.90 +27.4% | 2 qtrs — |
| 8 | NANTAHALA CAPITAL MANAGEMENT, LLC | 648.9K +— (+0.0%) | 3.22M +1.2M (+57.8%) | 1.87% +0.000 pp | 0.11% +0.036 pp | USD4.06 +22.4% | 8 qtrs — |
| 9 | LPL FINANCIAL LLC | 633.1K +301.9K (+91.1%) | 3.15M +2.1M (+201.5%) | 1.83% +0.870 pp | 0.00% +0.001 pp | USD4.95 +0.4% | 20 qtrs — |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 599.6K +92.6K (+18.3%) | 2.98M +1.4M (+86.6%) | 1.73% +0.267 pp | 0.00% +0.000 pp | USD4.81 +3.3% | 20 qtrs — |
| 11 | RAYMOND JAMES FINANCIAL INC | 599.7K +143.3K (+31.4%) | 2.98M +1.5M (+107.3%) | 1.73% +0.413 pp | 0.00% +0.001 pp | USD3.50 +42.0% | 5 qtrs — |
| 12 | GOLDMAN SACHS GROUP INC | 450.9K +227.1K (+101.5%) | 2.24M +1.5M (+217.9%) | 1.30% +0.655 pp | 0.00% +0.000 pp | USD4.28 +16.1% | 8 qtrs — |
| 13 | BLACKROCK, INC. | 419.1K +27.9K (+7.1%) | 2.08M +850.7K (+69.0%) | 1.21% +0.080 pp | 0.00% +0.000 pp | USD4.46 +11.4% | 6 qtrs — |
| 14 | JANE STREET GROUP, LLC | 382.2K +382.2K (+100.0%) | 1.90M +1.9M (+100.0%) | 1.10% +1.102 pp | 0.00% +0.000 pp | USD4.97 +0.0% | 3 qtrs — |
| 15 | PATHSTONE HOLDINGS, LLC | 416.7K -85.3K (-17.0%) | 1.86M +277.0K (+17.5%) | 1.20% -0.246 pp | 0.01% +0.001 pp | USD3.15 +57.8% | 2 qtrs — |
| 16 | UBS GROUP AG | 285.2K +206.1K (+260.4%) | 1.42M +1.2M (+468.6%) | 0.82% +0.594 pp | 0.00% +0.000 pp | USD4.52 +10.0% | 12 qtrs — |
| 17 | SHAY CAPITAL LLC | 234.9K -54.6K (-18.9%) | 1.17M +255.6K (+28.0%) | 0.68% -0.157 pp | 0.12% +0.042 pp | USD3.04 +63.5% | 20 qtrs — |
| 18 | STATE STREET CORP | 234.3K +13.9K (+6.3%) | 1.16M +470.0K (+67.7%) | 0.68% +0.040 pp | 0.00% +0.000 pp | USD4.42 +12.4% | 19 qtrs — |
| 19 | NORTHERN TRUST CORP | 229.9K +10.4K (+4.8%) | 1.14M +451.2K (+65.3%) | 0.66% +0.030 pp | 0.00% +0.000 pp | USD4.83 +2.9% | 19 qtrs — |
| 20 | 683 CAPITAL MANAGEMENT, LLC | 214.9K +214.9K (+100.0%) | 1.07M +1.1M (+100.0%) | 0.62% +0.620 pp | 0.05% +0.047 pp | USD4.97 +0.0% | 1 qtrs NEW |
| 21 | TWO SIGMA ADVISERS, LP | 209.9K +99.6K (+90.3%) | 1.04M +695.8K (+200.2%) | 0.61% +0.287 pp | 0.00% +0.001 pp | USD4.01 +23.9% | 2 qtrs — |
| 22 | BNP PARIBAS ARBITRAGE, SNC | 167.9K +167.6K (+54,075.8%) | 834.7K +833.7K (+85,333.7%) | 0.48% +0.483 pp | 0.00% +0.000 pp | USD4.97 +0.0% | 5 qtrs — |
| 23 | SQUAREPOINT OPS LLC | 164.6K -208.5K (-55.9%) | 818.1K -357.1K (-30.4%) | 0.47% -0.601 pp | 0.00% 0.000 pp | USD3.12 +59.3% | 5 qtrs — |
| 24 | RENAISSANCE TECHNOLOGIES LLC | 152.5K -158.3K (-50.9%) | 757.7K -221.2K (-22.6%) | 0.44% -0.456 pp | 0.00% 0.000 pp | USD3.15 +57.8% | 20 qtrs — |
| 25 | BARCLAYS PLC | 110.0K +62.4K (+130.9%) | 546.9K +321.0K (+142.1%) | 0.32% +0.180 pp | 0.00% +0.000 pp | USD4.20 +18.3% | 7 qtrs — |
| 26 | CITADEL ADVISORS LLC | 93.9K +69.7K (+288.0%) | 466.7K +390.5K (+512.2%) | 0.27% +0.201 pp | 0.00% +0.000 pp | USD4.50 +10.4% | 16 qtrs — |
| 27 | RONALD BLUE TRUST, INC. | 85.9K -13.2K (-13.4%) | 426.9K +114.6K (+36.7%) | 0.25% -0.038 pp | 0.00% +0.001 pp | USD3.15 +57.8% | 2 qtrs — |
| 28 | ALPINE GLOBAL MANAGEMENT, LLC | 83.5K +83.5K (+100.0%) | 414.9K +414.9K (+100.0%) | 0.24% +0.241 pp | 0.07% +0.075 pp | USD4.97 +0.0% | 3 qtrs — |
| 29 | MORGAN STANLEY | 79.1K +45.4K (+135.0%) | 392.9K +286.9K (+270.7%) | 0.23% +0.131 pp | 0.00% +0.000 pp | USD4.45 +11.7% | 7 qtrs — |
| 30 | POINT72 ASSET MANAGEMENT, L.P. | 75.2K +75.2K (+100.0%) | 373.6K +373.6K (+100.0%) | 0.22% +0.217 pp | 0.00% +0.000 pp | USD4.97 +0.0% | 1 qtrs NEW |
| 31 | WELLS FARGO & COMPANY/MN | 70.1K -1.5K (-2.1%) | 348.2K +122.7K (+54.4%) | 0.20% -0.004 pp | 0.00% +0.000 pp | USD4.58 +8.5% | 22 qtrs — |
| 32 | HUDSON BAY CAPITAL MANAGEMENT LP | 67.7K +67.7K (+100.0%) | 336.3K +336.3K (+100.0%) | 0.20% +0.195 pp | 0.00% +0.001 pp | USD4.97 +0.0% | 3 qtrs — |
| 33 | MANCHESTER FINANCIAL INC | 59.1K +12.4K (+26.6%) | 293.6K +146.6K (+99.7%) | 0.17% +0.036 pp | 0.05% +0.026 pp | USD3.74 +32.9% | 11 qtrs — |
| 34 | ADVISOR GROUP HOLDINGS, INC. | 54.0K +25.6K (+89.9%) | 268.3K +182.3K (+212.1%) | 0.16% +0.074 pp | 0.00% +0.000 pp | USD4.05 +22.7% | 18 qtrs — |
| 35 | DIMENSIONAL FUND ADVISORS LP | 52.4K +— (+0.0%) | 260.5K +95.4K (+57.8%) | 0.15% +0.000 pp | 0.00% +0.000 pp | USD3.15 +57.8% | 2 qtrs — |
| 36 | ADAR1 CAPITAL MANAGEMENT, LLC | 47.8K +— (+0.0%) | 237.6K +87.0K (+57.8%) | 0.14% +0.000 pp | 0.02% +0.003 pp | USD2.95 +68.5% | 8 qtrs — |
| 37 | GRAHAM CAPITAL MANAGEMENT, L.P. | 42.7K +42.7K (+100.0%) | 212.3K +212.3K (+100.0%) | 0.12% +0.123 pp | 0.01% +0.005 pp | USD4.97 +0.0% | 1 qtrs NEW |
| 38 | CAPTION MANAGEMENT, LLC | 37.7K +37.7K (+100.0%) | 187.3K +187.3K (+100.0%) | 0.11% +0.109 pp | 0.00% +0.001 pp | USD4.97 +0.0% | 1 qtrs NEW |
| 39 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 34.2K -37.9K (-52.6%) | 170.0K -57.1K (-25.2%) | 0.10% -0.109 pp | 0.00% +0.000 pp | USD3.02 +64.6% | 12 qtrs — |
| 40 | CITIGROUP INC | 33.0K +33.0K (+100.0%) | 163.9K +163.9K (+100.0%) | 0.10% +0.095 pp | 0.00% +0.000 pp | USD4.97 +0.0% | 1 qtrs NEW |
| 41 | MEMBERS WEALTH LLC | 30.0K +30.0K (+100.0%) | 152.7K +152.7K (+100.0%) | 0.09% +0.087 pp | 0.10% +0.096 pp | USD4.97 +0.0% | 1 qtrs NEW |
| 42 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 30.0K +— (+0.0%) | 149.1K +54.6K (+57.8%) | 0.09% +0.000 pp | 0.00% +0.000 pp | USD3.15 +57.8% | 2 qtrs — |
| 43 | — | 24.9K +24.9K (+100.0%) | 123.8K +123.8K (+100.0%) | 0.07% +0.072 pp | 0.02% +0.017 pp | USD4.97 +0.0% | 1 qtrs NEW |
| 44 | GOLDSTONE FINANCIAL GROUP, LLC | 24.2K +24.2K (+100.0%) | 120.1K +120.1K (+100.0%) | 0.07% +0.070 pp | 0.01% +0.013 pp | USD4.97 +0.0% | 1 qtrs NEW |
| 45 | BANK OF AMERICA CORP /DE/ | 24.1K -23.4K (-49.3%) | 119.5K -29.8K (-19.9%) | 0.07% -0.067 pp | 0.00% +0.000 pp | USD3.62 +37.3% | 13 qtrs — |
| 46 | LIGHTHOUSE INVESTMENT PARTNERS, LLC | 23.7K +23.7K (+100.0%) | 117.8K +117.8K (+100.0%) | 0.07% +0.068 pp | 0.00% +0.004 pp | USD4.97 +0.0% | 1 qtrs NEW |
| 47 | JUMP FINANCIAL, LLC | 21.0K +21.0K (+100.0%) | 104.4K +104.4K (+100.0%) | 0.06% +0.061 pp | 0.00% +0.001 pp | USD4.97 +0.0% | 1 qtrs NEW |
| 48 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 20.0K +20.0K (+100.0%) | 99.4K +99.4K (+100.0%) | 0.06% +0.058 pp | 0.00% +0.000 pp | USD4.97 +0.0% | 1 qtrs NEW |
| 49 | ROBERTSON STEPHENS WEALTH MANAGEMENT, LLC | 20.0K +10.0K (+100.0%) | 99.4K +67.9K (+215.6%) | 0.06% +0.029 pp | 0.00% +0.002 pp | USD4.06 +22.4% | 2 qtrs — |
| 50 | XTX TOPCO LTD | 19.1K -66.8K (-77.8%) | 94.9K -175.6K (-64.9%) | 0.06% -0.193 pp | 0.00% -0.012 pp | USD3.15 +57.8% | 4 qtrs — |
| 51 | HRT FINANCIAL LP | 18.9K +18.9K (+100.0%) | 93.0K +93.0K (+100.0%) | 0.05% +0.054 pp | 0.00% +0.000 pp | USD4.97 +0.0% | 1 qtrs NEW |
| 52 | SIMPLEX TRADING, LLC | 17.3K +17.3K (+100.0%) | 86.2K +86.2K (+100.0%) | 0.05% +0.050 pp | 0.00% +0.000 pp | USD4.97 +0.0% | 4 qtrs — |
| 53 | JEFFERIES FINANCIAL GROUP INC. | 16.8K +16.8K (+100.0%) | 83.6K +83.6K (+100.0%) | 0.05% +0.049 pp | 0.00% +0.000 pp | USD4.97 +0.0% | 1 qtrs NEW |
| 54 | NEXT CAPITAL MANAGEMENT LLC | 16.1K +— (+0.0%) | 80.2K +29.4K (+57.8%) | 0.05% +0.000 pp | 0.03% +0.009 pp | USD3.15 +57.8% | 2 qtrs — |
| 55 | SBI SECURITIES CO., LTD. | 14.0K +1.0 (+0.0%) | 69.8K +25.6K (+57.8%) | 0.04% +0.000 pp | 0.00% +0.001 pp | USD3.52 +41.2% | 5 qtrs — |
| 56 | QUBE RESEARCH & TECHNOLOGIES LTD | 13.4K -36.3K (-73.0%) | 66.6K -89.8K (-57.4%) | 0.04% -0.105 pp | 0.00% 0.000 pp | USD2.26 +119.9% | 3 qtrs — |
| 57 | MAGNOLIA CAPITAL ADVISORS LLC | 12.9K +12.9K (+100.0%) | 63.9K +63.9K (+100.0%) | 0.04% +0.037 pp | 0.01% +0.013 pp | USD4.97 +0.0% | 1 qtrs NEW |
| 58 | WINDSOR CAPITAL MANAGEMENT, LLC | 10.8K +— (+0.0%) | 53.8K +19.7K (+57.8%) | 0.03% +0.000 pp | 0.01% +0.005 pp | USD4.74 +4.9% | 6 qtrs — |
| 59 | MADISON PARK CAPITAL ADVISORS, LLC | 10.0K +— (+0.0%) | 49.7K +18.2K (+57.8%) | 0.03% +0.000 pp | 0.04% +0.015 pp | USD4.12 +20.6% | 9 qtrs — |
| 60 | FMR LLC | 6.5K -473.0 (-6.8%) | 32.4K +10.4K (+47.1%) | 0.02% -0.001 pp | 0.00% +0.000 pp | USD2.73 +82.1% | 6 qtrs — |
| 61 | STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 4.6K +4.6K (+100.0%) | 23.1K +23.1K (+100.0%) | 0.01% +0.013 pp | 0.00% +0.000 pp | USD4.97 +0.0% | 1 qtrs NEW |
| 62 | ALLWORTH FINANCIAL LP | 3.0K +— (+0.0%) | 14.9K +5.5K (+57.8%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD4.78 +4.0% | 7 qtrs — |
| 63 | TOWER RESEARCH CAPITAL LLC (TRC) | 2.8K +2.8K (+100.0%) | 14.0K +14.0K (+100.0%) | 0.01% +0.008 pp | 0.00% +0.000 pp | USD4.97 +0.0% | 21 qtrs — |
| 64 | COMERICA BANK | 2.4K -31.0 (-1.3%) | 11.8K +4.2K (+55.8%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD4.30 +15.6% | 10 qtrs — |
| 65 | FEDERATION DES CAISSES DESJARDINS DU QUEBEC | 2.0K +— (+0.0%) | 9.9K +3.6K (+57.8%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD3.15 +57.8% | 2 qtrs — |
| 66 | CWM, LLC | 1.7K +— (+0.0%) | 8.0K +3.0K (+60.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.11 +59.8% | 6 qtrs — |
| 67 | ROYAL BANK OF CANADA | 1.5K -153.2K (-99.0%) | 8.0K -479.0K (-98.4%) | 0.00% -0.442 pp | 0.00% 0.000 pp | USD2.50 +98.8% | 7 qtrs — |
| 68 | CAPITAL ANALYSTS, LLC | 700.00 +190.0 (+37.3%) | 3.0K +1.0K (+50.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD3.64 +36.5% | 2 qtrs — |
| 69 | SITTNER & NELSON, LLC | 673.00 +— (+0.0%) | 2.9K +741.0 (+35.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.15 +57.8% | 2 qtrs — |
| 70 | OPTIVER HOLDING B.V. | 490.00 +— (+0.0%) | 2.4K +891.0 (+57.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.15 +57.8% | 2 qtrs — |
| 71 | JONES FINANCIAL COMPANIES LLLP | 200.00 +200.0 (+100.0%) | 994.00 +994.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD4.97 +0.0% | 1 qtrs NEW |
| 72 | RUSSELL INVESTMENTS GROUP, LTD. | 150.00 +— (+0.0%) | 746.00 +273.0 (+57.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.37 +13.7% | 6 qtrs — |
| 73 | CORNERSTONE PLANNING GROUP LLC | 100.00 +87.0 (+669.2%) | 436.00 -4.2K (-90.7%) | 0.00% +0.000 pp | 0.00% -0.001 pp | USD4.91 +1.2% | 10 qtrs — |
| 74 | JPMORGAN CHASE & CO | 19.00 +— (+0.0%) | 94.00 +34.0 (+56.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.79 +31.1% | 7 qtrs — |
| 75 | SRS CAPITAL ADVISORS, INC. | 10.00 +— (+0.0%) | 50.00 +19.0 (+61.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.10 +60.3% | 2 qtrs — |
| 76 | PARKSIDE FINANCIAL BANK & TRUST | 5.00 +5.0 (+100.0%) | 25.00 +25.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.80 +3.5% | 1 qtrs NEW |
| 77 | FNY INVESTMENT ADVISERS, LLC | — -5.0K (-100.0%) | — -15.0K (-100.0%) | 0.00% -0.014 pp | 0.00% -0.005 pp | USD— | 2 qtrs SOLD |
| 78 | OMERS ADMINISTRATION CORP | — -24.7K (-100.0%) | — -77.8K (-100.0%) | 0.00% -0.071 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 79 | RESOURCES INVESTMENT ADVISORS, LLC. | — -20.0K (-100.0%) | — -63.0K (-100.0%) | 0.00% -0.058 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 80 | SENDER CO & PARTNERS, INC. | — -25.0K (-100.0%) | — -78.8K (-100.0%) | 0.00% -0.072 pp | 0.00% -0.009 pp | USD— | 3 qtrs SOLD |
| 81 | GROUP ONE TRADING, L.P. | — -8.8K (-100.0%) | — -27.7K (-100.0%) | 0.00% -0.025 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 82 | PNC FINANCIAL SERVICES GROUP, INC. | — -826.0 (-100.0%) | — -2.6K (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 83 | STEPHENS CONSULTING, LLC | — -3.0K (-100.0%) | — -9.5K (-100.0%) | 0.00% -0.009 pp | 0.00% -0.003 pp | USD— | 14 qtrs SOLD |
| 84 | CLEARLINE CAPITAL LP | — -451.2K (-100.0%) | — -1.4M (-100.0%) | 0.00% -1.301 pp | 0.00% -0.065 pp | USD— | 3 qtrs SOLD |
| 85 | BERKSHIRE ASSET MANAGEMENT LLC/PA | — -17.7K (-100.0%) | — -55.8K (-100.0%) | 0.00% -0.051 pp | 0.00% -0.002 pp | USD— | 7 qtrs SOLD |
| 86 | ALYESKA INVESTMENT GROUP, L.P. | — -178.4K (-100.0%) | — -561.9K (-100.0%) | 0.00% -0.514 pp | 0.00% -0.002 pp | USD— | 8 qtrs SOLD |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
6
Sells
0
Shares acquired
1.44M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+1,435,300
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-18 | Goldberg Andrew D. | Director / Officer | A-Award | A | Performance Restricted Stock Unit (PRSU) | 11,706,270 | 0.00 | — | 11,706,270 | D | ↗ |
| 2026-04-17 | TPG GP A, LLC | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 6,877,580 | I | ↗ |
| 2026-04-17 | Royston Aaron | Director | — | — | No securities are beneficially owned | 0 | 0.00 | — | 0 | D | ↗ |
| 2026-04-17 | Iancovici Lucian | Director | — | — | No securities beneficially owned | 0 | 0.00 | — | 0 | D | ↗ |
| 2026-01-28 | Xinos Jaime | Officer | A-Award | A | Stock Option (right to buy) | 180,000 | 4.36 | 784.8K | 180,000 | D | ↗ |
| 2026-01-28 | Wan Jerry | Officer | A-Award | A | Stock Option (right to buy) | 70,300 | 4.36 | 306.5K | 70,300 | D | ↗ |
| 2026-01-28 | Stewart Richard Alistair | Director / Officer | A-Award | A | Stock Option (right to buy) | 645,000 | 4.36 | 2.81M | 645,000 | D | ↗ |
| 2026-01-28 | Rubinstein Mark Lawrence | Officer | A-Award | A | Stock Option (right to buy) | 180,000 | 4.36 | 784.8K | 180,000 | D | ↗ |
| 2026-01-28 | Oki Mark K | Officer | A-Award | A | Stock Option (right to buy) | 180,000 | 4.36 | 784.8K | 180,000 | D | ↗ |
| 2026-01-28 | Donnelly Craig | Officer | A-Award | A | Stock Option (right to buy) | 180,000 | 4.36 | 784.8K | 180,000 | D | ↗ |
| 2026-01-01 | Rubinstein Mark Lawrence | Officer | — | — | Common Stock | 0 | 0.00 | — | 39,600 | D | ↗ |
| 2025-12-04 | Atkisson Erik | Officer | A-Award | A | Stock Option (right to buy) | 250,000 | 4.78 | 1.20M | 250,000 | D | ↗ |
| 2025-10-20 | Atkisson Erik | Officer | — | — | No securities are beneficially owned | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-10-01 | Donnelly Craig | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 3.10 | 155.0K | 50,000 | D | ↗ |
| 2025-09-18 | Stewart Richard Alistair | Director / Officer | M-Exempt | A | Common Stock | 297,500 | 0.00 | — | 358,376 | D | ↗ |
| 2025-09-18 | Oki Mark K | Officer | M-Exempt | A | Common Stock | 168,000 | 0.00 | — | 178,000 | D | ↗ |
| 2025-09-08 | Donnelly Craig | Officer | — | — | Stock Option (right to buy) | 25,000 | 4.53 | 113.3K | 0 | D | ↗ |
| 2025-09-04 | Xinos Jaime | Officer | M-Exempt | D | Performance Restricted Stock Unit (PRSU) | 49,000 | 0.00 | — | 0 | D | ↗ |
| 2025-09-04 | Wan Jerry | Officer | M-Exempt | D | Performance Restricted Stock Unit (PRSU) | 24,500 | 0.00 | — | 0 | D | ↗ |
| 2025-09-04 | Stewart Richard Alistair | Director / Officer | A-Award | D | Performance Restricted Stock Unit | 157,500 | 0.00 | — | 0 | D | ↗ |
| 2025-09-04 | Oki Mark K | Officer | A-Award | D | Performance Restricted Stock Unit | 168,000 | 0.00 | — | 0 | D | ↗ |
| 2025-09-04 | KING THOMAS BRAXTON | Director | M-Exempt | D | Performance Restricted Stock Unit (PRSU) | 455,000 | 0.00 | — | 0 | D | ↗ |
| 2025-09-04 | JACOBS CINDY | Officer | M-Exempt | D | Performance Restricted Stock Unit (PRSU) | 84,000 | 0.00 | — | 0 | D | ↗ |
| 2025-06-06 | Slaoui Kristen B. | Director | A-Award | A | Stock Option (right to buy) | 31,500 | 3.83 | 120.6K | 31,500 | D | ↗ |
| 2025-06-06 | Sellig Thomas | Director | A-Award | A | Stock Option (right to buy) | 31,500 | 3.83 | 120.6K | 31,500 | D | ↗ |
| 2025-06-06 | Phelan Nancy R. | Director | A-Award | A | Stock Option (right to buy) | 31,500 | 3.83 | 120.6K | 31,500 | D | ↗ |
| 2025-06-06 | Martell Bridget A | Director | A-Award | A | Stock Option (right to buy) | 31,500 | 3.83 | 120.6K | 31,500 | D | ↗ |
| 2025-06-06 | KING THOMAS BRAXTON | Director | A-Award | A | Stock Option (right to buy) | 31,500 | 3.83 | 120.6K | 31,500 | D | ↗ |
| 2025-06-06 | Duty Stuart | Director | A-Award | A | Stock Option (right to buy) | 31,500 | 3.83 | 120.6K | 31,500 | D | ↗ |
| 2025-03-17 | Stewart Richard Alistair | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 2.86 | 28.6K | 60,876 | D | ↗ |
| 2025-03-17 | Oki Mark K | Officer | P-Purchase | A | Common Stock | 10,000 | 2.89 | 28.9K | 10,000 | D | ↗ |
| 2025-01-28 | Xinos Jaime | Officer | A-Award | A | Performance Restricted Stock Unit (PRSU) | 100,000 | 0.00 | — | 100,000 | D | ↗ |
| 2025-01-28 | Wan Jerry | Officer | A-Award | A | Performance Restricted Stock Unit (PRSU) | 48,000 | 0.00 | — | 48,000 | D | ↗ |
| 2025-01-28 | JACOBS CINDY | Director / Officer | A-Award | A | Performance Restricted Stock Unit (PRSU) | 130,000 | 0.00 | — | 130,000 | D | ↗ |
| 2025-01-13 | Xinos Jaime | Officer | A-Award | A | Stock Option (right to buy) | 20,000 | 3.32 | 66.4K | 20,000 | D | ↗ |
| 2025-01-13 | Stewart Richard Alistair | Director / Officer | A-Award | A | Performance Restricted Stock Unit (PRSU) | 157,500 | 0.00 | — | 157,500 | D | ↗ |
| 2025-01-13 | Slaoui Kristen B. | Director | A-Award | A | Stock Option (right to buy) | 47,250 | 3.32 | 156.9K | 47,250 | D | ↗ |
| 2025-01-13 | Phelan Nancy R. | Director | A-Award | A | Stock Option (right to buy) | 47,250 | 3.32 | 156.9K | 47,250 | D | ↗ |
| 2025-01-13 | KING THOMAS BRAXTON | Director / Officer | A-Award | A | Performance Restricted Stock Unit (PRSU) | 455,000 | 0.00 | — | 455,000 | D | ↗ |
| 2025-01-06 | Slaoui Kristen B. | Director | — | — | No securities are beneficially owned | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-01-06 | Phelan Nancy R. | Director | — | — | No securities are beneficially owned | 0 | 0.00 | — | 0 | D | ↗ |
| 2024-12-06 | Xinos Jaime | Officer | A-Award | A | Stock Option (right to buy) | 30,000 | 4.52 | 135.6K | 30,000 | D | ↗ |
| 2024-12-06 | Oki Mark K | Officer | A-Award | A | Performance Restricted Stock Unit (PRSU) | 168,000 | 0.00 | — | 168,000 | D | ↗ |
| 2024-12-05 | Oki Mark K | Officer | — | — | No securities are beneficially owned | 0 | 0.00 | — | 0 | D | ↗ |
| 2024-10-15 | Xinos Jaime | Officer | — | — | Stock Option (right to buy) | 1,000 | 67.40 | 67.4K | 0 | D | ↗ |
| 2024-08-16 | Wan Jerry | Officer | A-Award | A | Common Stock | 2,857 | 3.67 | 10.5K | 12,664 | — | ↗ |
| 2024-08-16 | JACOBS CINDY | Director / Officer | A-Award | A | Common Stock | 2,660 | 3.67 | 9.8K | 33,214 | — | ↗ |
| 2024-08-16 | Bencich John | Director / Officer | A-Award | A | Common Stock | 5,000 | 3.67 | 18.4K | 100,636 | — | ↗ |
| 2024-04-19 | Wan Jerry | Officer | M-Exempt | A | Common Stock | 5,625 | 0.00 | — | 12,057 | — | ↗ |
| 2024-04-19 | Stewart Richard Alistair | Director / Officer | M-Exempt | A | Common Stock | 22,500 | 0.00 | — | 61,001 | — | ↗ |
| 2024-04-19 | JACOBS CINDY | Director / Officer | M-Exempt | D | Performance Restricted Stock Unit (PRSU) | 16,250 | 0.00 | — | 0 | — | ↗ |
| 2024-04-19 | Bencich John | Director / Officer | M-Exempt | D | Performance Restricted Stock Unit (PRSU) | 25,000 | 0.00 | — | 0 | — | ↗ |
| 2024-03-04 | Stewart Richard Alistair | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 4.59 | 45.9K | 38,501 | — | ↗ |
| 2024-03-04 | Bencich John | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 4.59 | 45.9K | 76,724 | — | ↗ |
| 2024-01-22 | Wan Jerry | Officer | A-Award | A | Stock Option (right to buy) | 10,500 | 4.55 | 47.8K | 10,500 | — | ↗ |
| 2024-01-22 | Stewart Richard Alistair | Director / Officer | A-Award | A | Stock Option (right to buy) | 60,000 | 4.55 | 273.0K | 60,000 | — | ↗ |
| 2024-01-22 | Sellig Thomas | Director | A-Award | A | Stock Option (right to buy) | 31,500 | 4.55 | 143.3K | 31,500 | — | ↗ |
| 2024-01-22 | Martell Bridget A | Director | A-Award | A | Stock Option (right to buy) | 31,500 | 4.55 | 143.3K | 31,500 | — | ↗ |
| 2024-01-22 | KING THOMAS BRAXTON | Director | A-Award | A | Stock Option (right to buy) | 31,500 | 4.55 | 143.3K | 31,500 | — | ↗ |
| 2024-01-22 | JACOBS CINDY | Director / Officer | A-Award | A | Stock Option (right to buy) | 36,000 | 4.55 | 163.8K | 36,000 | — | ↗ |
| 2024-01-22 | HIMES VAUGHN B | Director | A-Award | A | Stock Option (right to buy) | 31,500 | 4.55 | 143.3K | 31,500 | — | ↗ |
| 2024-01-22 | Duty Stuart | Director | A-Award | A | Stock Option (right to buy) | 31,500 | 4.55 | 143.3K | 31,500 | — | ↗ |
| 2024-01-22 | Bencich John | Director / Officer | A-Award | A | Performance Restricted Stock Unit (PRSU) | 175,000 | 0.00 | — | 175,000 | — | ↗ |
| 2023-06-07 | Martell Bridget A | Director | A-Award | A | Stock Option (right to buy) | 31,500 | 6.00 | 189.0K | 31,500 | — | ↗ |
| 2023-06-07 | HIMES VAUGHN B | Director | A-Award | A | Stock Option (right to buy) | 31,500 | 6.00 | 189.0K | 31,500 | — | ↗ |
| 2023-05-30 | Bencich John | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 5.50 | 27.5K | 66,730 | — | ↗ |
| 2023-05-18 | DIALECTIC CAPITAL MANAGEMENT, LP | Director | — | I | Common Stock Warrants (right to buy) | 1,747,000 | 4.50 | 7.86M | — | — | ↗ |
| 2023-04-28 | Wan Jerry | Officer | M-Exempt | D | Performance Restricted Stock Unit (PRSU) | 1,250 | 0.00 | — | 0 | — | ↗ |
| 2023-04-28 | Stewart Richard Alistair | Director / Officer | M-Exempt | D | Performance Restricted Stock Unit (PRSU) | 5,000 | 0.00 | — | 0 | — | ↗ |
| 2023-04-28 | JACOBS CINDY | Director / Officer | F-InKind | D | Common Stock | 609 | 8.29 | 5.0K | 18,261 | — | ↗ |
| 2023-04-28 | Bencich John | Director / Officer | M-Exempt | D | Performance Restricted Stock Unit (PRSU) | 7,500 | 0.00 | — | 0 | — | ↗ |
| 2023-04-21 | Wan Jerry | Officer | M-Exempt | A | Performance Restricted Stock Unit (PRSU) | 5,625 | 0.00 | — | 5,625 | — | ↗ |
| 2023-04-21 | Stewart Richard Alistair | Director / Officer | M-Exempt | A | Common Stock | 22,500 | 0.00 | — | 35,876 | — | ↗ |
| 2023-04-21 | JACOBS CINDY | Director / Officer | F-InKind | D | Common Stock | 4,819 | 6.80 | 32.8K | 15,362 | — | ↗ |
| 2023-04-21 | Bencich John | Director / Officer | M-Exempt | A | Performance Restricted Stock Unit (PRSU) | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2023-03-29 | Sellig Thomas | Director | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-03-29 | KING THOMAS BRAXTON | Director | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-03-29 | Duty Stuart | Director | A-Award | A | Stock Option (right to buy) | 24,000 | 5.97 | 143.3K | 24,000 | — | ↗ |
| 2023-01-25 | Wan Jerry | Officer | A-Award | A | Stock Option (right to buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2023-01-25 | Stewart Richard Alistair | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 0.00 | — | 75,000 | — | ↗ |
| 2023-01-25 | JACOBS CINDY | Officer | A-Award | A | Stock Option (right to buy) | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2023-01-25 | Bencich John | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2022-11-18 | SVB FINANCIAL GROUP | 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-11-18 | DIALECTIC CAPITAL MANAGEMENT, LP | Director | — | I | Common Stock, par value $0.001 per share | 0 | 0.00 | — | 55,000 | — | ↗ |
| 2022-11-18 | Bencich John | Officer | P-Purchase | A | Common Stock | 22,000 | 0.00 | — | 36,920 | — | ↗ |
| 2022-11-01 | SVB FINANCIAL GROUP | Director | J-Other | A | Convertible Debt (PIK Amount) | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-10-03 | SVB FINANCIAL GROUP | 10% Owner | J-Other | A | Convertible Debt (PIK Amount) | 0 | 9.34 | — | 0 | — | ↗ |
| 2022-10-03 | Innovation Credit Fund VIII-A, L.P. | Director | J-Other | A | Convertible Debt (PIK Amount) | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-09-01 | SVB FINANCIAL GROUP | 10% Owner | J-Other | A | Convertible Debt (PIK Amount) | 0 | 9.34 | — | 0 | — | ↗ |
| 2022-09-01 | Innovation Credit Fund VIII-A, L.P. | Director | J-Other | A | Convertible Debt (PIK Amount) | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-08-16 | Wan Jerry | Officer | F-InKind | D | Common Stock | 266 | 4.37 | 1.2K | 3,236 | — | ↗ |
| 2022-08-16 | JACOBS CINDY | Officer | A-Award | A | Common Stock | 1,817 | 4.37 | 7.9K | 3,931 | — | ↗ |
| 2022-08-16 | Bencich John | Officer | A-Award | A | Common Stock | 3,059 | 4.37 | 13.4K | 14,920 | — | ↗ |
| 2022-08-01 | SVB FINANCIAL GROUP | 10% Owner | J-Other | A | Convertible Debt (PIK Amount) | 0 | 9.34 | — | 0 | — | ↗ |
| 2022-08-01 | Innovation Credit Fund VIII-A, L.P. | Director | J-Other | A | Convertible Debt (PIK Amount) | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-07-01 | SVB FINANCIAL GROUP | 10% Owner | J-Other | A | Convertible Debt (PIK Amount) | 45,137 | 9.34 | 421.6K | 7,782,974 | — | ↗ |
| 2022-07-01 | Innovation Credit Fund VIII-A, L.P. | Director | J-Other | A | Convertible Debt (PIK Amount) | 22,569 | 0.00 | — | 3,891,487 | — | ↗ |
| 2022-06-01 | SVB FINANCIAL GROUP | 10% Owner | J-Other | A | Convertible Debt (PIK Amount) | 44,876 | 9.34 | 419.1K | 7,737,836 | — | ↗ |
| 2022-06-01 | Innovation Credit Fund VIII-A, L.P. | Director | J-Other | A | Convertible Debt (PIK Amount) | 22,438 | 0.00 | — | 3,868,918 | — | ↗ |
| 2022-05-31 | Martell Bridget A | Director | A-Award | A | Stock Option (right to buy) | 4,400 | 0.00 | — | 4,400 | — | ↗ |
| 2022-05-31 | MOYES JAY M | Director | A-Award | A | Stock Option (right to buy) | 4,400 | 0.00 | — | 4,400 | — | ↗ |
| 2022-05-31 | MATTINGLY MARTIN A | Director | A-Award | A | Stock Option (right to buy) | 4,400 | 0.00 | — | 4,400 | — | ↗ |
| 2022-05-31 | Joseph Donald | Director | A-Award | A | Stock Option (right to buy) | 4,400 | 6.90 | 30.4K | 4,400 | — | ↗ |
| 2022-05-02 | SVB FINANCIAL GROUP | 10% Owner | J-Other | A | Convertible Debt (PIK Amount) | 46,094 | 9.34 | 430.5K | 7,692,961 | — | ↗ |
| 2022-05-02 | Innovation Credit Fund VIII-A, L.P. | Director | J-Other | A | Convertible Debt (PIK Amount) | 46,094 | 0.00 | — | 7,692,961 | — | ↗ |
| 2022-04-28 | Wan Jerry | Officer | F-InKind | D | Common Stock | 669 | 7.43 | 5.0K | 675 | — | ↗ |
| 2022-04-28 | Stewart Richard Alistair | Officer | F-InKind | D | Common Stock | 2,250 | 7.43 | 16.7K | 13,376 | — | ↗ |
| 2022-04-28 | JACOBS CINDY | Officer | F-InKind | D | Common Stock | 609 | 7.43 | 4.5K | 2,114 | — | ↗ |
| 2022-04-28 | Clarke Anthony | Officer | F-InKind | D | Common Stock | 250 | 7.43 | 1.9K | 3,502 | — | ↗ |
| 2022-04-28 | Bencich John | Officer | M-Exempt | A | Common Stock | 7,500 | 0.00 | — | 13,688 | — | ↗ |
| 2022-04-01 | SVB FINANCIAL GROUP | 10% Owner | J-Other | A | Convertible Debt (PIK Amount) | 0 | 9.34 | — | 0 | — | ↗ |
| 2022-04-01 | Innovation Credit Fund VIII-A, L.P. | Director | J-Other | A | Convertible Debt (PIK Amount) | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-03-14 | HIMES VAUGHN B | Director | A-Award | A | Stock Option (right to buy) | 6,600 | 0.00 | — | 6,600 | — | ↗ |
| 2022-03-01 | SVB FINANCIAL GROUP | 10% Owner | J-Other | A | Convertible Debt (PIK Amount) | 0 | 9.34 | — | 0 | — | ↗ |
| 2022-03-01 | Innovation Credit Fund VIII-A, L.P. | Director | J-Other | A | Convertible Debt (PIK Amount) | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-02-01 | SVB FINANCIAL GROUP | 10% Owner | J-Other | A | Convertible Debt (PIK Amount) | 0 | 9.34 | — | 0 | — | ↗ |
| 2022-01-03 | Wan Jerry | Officer | A-Award | A | Stock Option (right to buy) | 11,250 | 8.26 | 92.9K | 11,250 | — | ↗ |
| 2022-01-03 | Stewart Richard Alistair | Director / Officer | A-Award | A | Stock Option (right to buy) | 45,000 | 8.26 | 371.7K | 45,000 | — | ↗ |
| 2022-01-03 | SVB FINANCIAL GROUP | 10% Owner | J-Other | A | Convertible Debt (PIK Amount) | 0 | 9.34 | — | 0 | — | ↗ |
| 2022-01-03 | JACOBS CINDY | Director / Officer | A-Award | A | Stock Option (right to buy) | 32,500 | 8.26 | 268.5K | 32,500 | — | ↗ |
| 2022-01-03 | Clarke Anthony | Officer | A-Award | A | Performance Restricted Stock Unit (PRSU) | 7,500 | 0.00 | — | 7,500 | — | ↗ |
| 2022-01-03 | Bencich John | Director / Officer | A-Award | A | Performance Restricted Stock Unit (PRSU) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2021-12-22 | SVB FINANCIAL GROUP | 10% Owner | — | I | Convertible Debt | 401,498 | 0.00 | — | 0 | — | ↗ |
| 2021-08-17 | Wan Jerry | Officer | F-InKind | D | Common Stock | 6 | 6.81 | 40.86 | 94 | — | ↗ |
| 2021-08-17 | JACOBS CINDY | Director / Officer | F-InKind | D | Common Stock | 21 | 6.81 | 143.01 | 223 | — | ↗ |
| 2021-08-17 | Bencich John | Director / Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 68 | 0.00 | — | 0 | — | ↗ |
| 2021-05-27 | Bencich John | Director / Officer | P-Purchase | A | Common Stock | 6,000 | 7.00 | 42.0K | 6,141 | — | ↗ |
| 2021-05-11 | MOYES JAY M | Director | A-Award | A | Stock Option (right to buy) | 3,750 | 9.90 | 37.1K | 3,750 | — | ↗ |
| 2021-05-11 | MATTINGLY MARTIN A | Director | A-Award | A | Stock Option (right to buy) | 3,750 | 9.90 | 37.1K | 3,750 | — | ↗ |
| 2021-05-11 | Joseph Donald | Director | A-Award | A | Stock Option (right to buy) | 3,750 | 9.90 | 37.1K | 3,750 | — | ↗ |
| 2021-03-15 | Martell Bridget A | Director | A-Award | A | Stock Option (right to buy) | 5,650 | 12.10 | 68.4K | 5,650 | — | ↗ |
| 2021-01-26 | Wann Jerry | Officer | A-Award | A | Performance Restricted Stock Unit (PRSU) | 2,500 | 0.00 | — | 2,500 | — | ↗ |
| 2021-01-26 | Stewart Richard Alistair | Director / Officer | A-Award | A | Performance Restricted Stock Unit (PRSU) | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2021-01-26 | JACOBS CINDY | Officer | A-Award | A | Performance Restricted Stock Unit (PRSU) | 5,000 | 0.00 | — | 5,000 | — | ↗ |
| 2021-01-26 | Clarke Anthony | Officer | A-Award | A | Performance Restricted Stock Unit (PRSU) | 2,000 | 0.00 | — | 2,000 | — | ↗ |
| 2021-01-26 | Bencich John | Director / Officer | A-Award | A | Performance Restricted Stock Unit (PRSU) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2020-11-16 | Wann Jerry | Officer | A-Award | A | Stock Option (right to buy) | 7,500 | 10.36 | 77.7K | 7,500 | — | ↗ |
| 2020-11-16 | Stewart Richard Alistair | Director / Officer | A-Award | A | Stock Option (right to buy) | 15,000 | 10.36 | 155.4K | 15,000 | — | ↗ |
| 2020-11-16 | JACOBS CINDY | Officer | A-Award | A | Stock Option (right to buy) | 12,000 | 10.36 | 124.3K | 12,000 | — | ↗ |
| 2020-11-16 | Clarke Anthony | Officer | A-Award | A | Stock Option (right to buy) | 12,000 | 10.36 | 124.3K | 12,000 | — | ↗ |
| 2020-11-16 | Bencich John | Director / Officer | A-Award | A | Stock Option (right to buy) | 20,000 | 10.36 | 207.2K | 20,000 | — | ↗ |
| 2020-09-28 | Wann Jerry | Officer | — | D | Common Stock | 0 | 0.00 | — | 89 | — | ↗ |
| 2020-08-18 | JACOBS CINDY | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 69 | 0.00 | — | 68 | — | ↗ |
| 2020-08-18 | Bencich John | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 69 | 0.00 | — | 68 | — | ↗ |
| 2020-05-12 | PARKER H STEWART | Director | A-Award | A | Stock Option (right to buy) | 22,000 | 0.43 | 9.5K | 22,000 | — | ↗ |
| 2020-05-12 | MOYES JAY M | Director | A-Award | A | Stock Option (right to buy) | 22,000 | 0.43 | 9.5K | 22,000 | — | ↗ |
| 2020-05-12 | MATTINGLY MARTIN A | Director | A-Award | A | Stock Option (right to buy) | 22,000 | 0.43 | 9.5K | 22,000 | — | ↗ |
| 2020-05-12 | Joseph Donald | Director | A-Award | A | Stock Option (right to buy) | 22,000 | 0.43 | 9.5K | 22,000 | — | ↗ |
| 2020-05-12 | Cormack Scott Daniel | Director | A-Award | A | Stock Option (right to buy) | 22,000 | 0.43 | 9.5K | 22,000 | — | ↗ |
| 2020-01-28 | Stewart Richard Alistair | Director / Officer | A-Award | A | Stock Option (right to buy) | 450,000 | 0.56 | 252.0K | 450,000 | — | ↗ |
| 2020-01-28 | JACOBS CINDY | Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 0.56 | 112.0K | 200,000 | — | ↗ |
| 2020-01-28 | Clarke Anthony | Director / Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 0.56 | 112.0K | 200,000 | — | ↗ |
| 2020-01-28 | Bencich John | Officer | A-Award | A | Stock Option (right to buy) | 200,000 | 0.56 | 112.0K | 200,000 | — | ↗ |
| 2019-08-13 | JACOBS CINDY | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 1,370 | 0.00 | — | 2,740 | — | ↗ |
| 2019-08-13 | Bencich John | Officer | F-InKind | D | Common Stock | 408 | 1.88 | 767.04 | 2,101 | — | ↗ |
| 2019-06-11 | ARMISTICE CAPITAL, LLC | 10% Owner | S-Sale | D | Common Stock | 3,000 | 2.53 | 7.6K | 893,776 | — | ↗ |
| 2019-05-30 | ARMISTICE CAPITAL, LLC | 10% Owner | — | I | Common Stock, par value $0.001 per share | 0 | 0.00 | — | 1,095,926 | — | ↗ |
| 2019-05-23 | Stewart Richard Alistair | Director / Officer | P-Purchase | A | Common Stock | 17,500 | 3.61 | 63.1K | 212,530 | — | ↗ |
| 2019-05-14 | PARKER H STEWART | Director | A-Award | A | Stock Option (right to buy) | 7,000 | 4.02 | 28.1K | 7,000 | — | ↗ |
| 2019-05-14 | MOYES JAY M | Director | A-Award | A | Stock Option (right to buy) | 7,000 | 4.02 | 28.1K | 7,000 | — | ↗ |
| 2019-05-14 | MATTINGLY MARTIN A | Director | A-Award | A | Stock Option (right to buy) | 7,000 | 4.02 | 28.1K | 7,000 | — | ↗ |
| 2019-05-14 | Joseph Donald | Director | A-Award | A | Stock Option (right to buy) | 7,000 | 4.02 | 28.1K | 7,000 | — | ↗ |
| 2019-05-14 | Cormack Scott Daniel | Director | A-Award | A | Stock Option (right to buy) | 7,000 | 4.02 | 28.1K | 7,000 | — | ↗ |
| 2019-01-29 | Stewart Richard Alistair | Director / Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 1.42 | 106.5K | 75,000 | — | ↗ |
| 2019-01-29 | JACOBS CINDY | Officer | A-Award | A | Stock Option (right to buy) | 30,000 | 1.42 | 42.6K | 30,000 | — | ↗ |
| 2019-01-29 | Clarke Anthony | Director / Officer | A-Award | A | Stock Option (right to buy) | 30,000 | 1.42 | 42.6K | 30,000 | — | ↗ |
| 2019-01-29 | Bencich John | Officer | A-Award | A | Stock Option (right to buy) | 30,000 | 1.42 | 42.6K | 30,000 | — | ↗ |
| 2019-01-15 | JACOBS CINDY | Officer | F-InKind | D | Common Stock | 13 | 1.16 | 15.08 | 1,839 | — | ↗ |
| 2019-01-15 | Bencich John | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 28 | 0.00 | — | 0 | — | ↗ |
| 2018-09-20 | Stewart Richard Alistair | Director / Officer | A-Award | A | Stock Option (right to buy) | 101,000 | 2.56 | 258.6K | 101,000 | — | ↗ |
| 2018-09-20 | PARKER H STEWART | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 2.56 | 30.7K | 12,000 | — | ↗ |
| 2018-09-20 | MOYES JAY M | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 2.56 | 30.7K | 12,000 | — | ↗ |
| 2018-09-20 | MATTINGLY MARTIN A | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 2.56 | 30.7K | 12,000 | — | ↗ |
| 2018-09-20 | Joseph Donald | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 2.56 | 30.7K | 12,000 | — | ↗ |
| 2018-09-20 | JACOBS CINDY | Officer | A-Award | A | Stock Option (right to buy) | 37,000 | 2.56 | 94.7K | 37,000 | — | ↗ |
| 2018-09-20 | Cormack Scott Daniel | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 2.56 | 30.7K | 12,000 | — | ↗ |
| 2018-09-20 | Clarke Anthony | Director / Officer | A-Award | A | Stock Option (right to buy) | 37,000 | 2.56 | 94.7K | 37,000 | — | ↗ |
| 2018-09-20 | Bencich John | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 2.56 | 128.0K | 50,000 | — | ↗ |
| 2018-08-13 | JACOBS CINDY | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 45 | 0.00 | — | 0 | — | ↗ |
| 2018-08-13 | Bencich John | Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 45 | 0.00 | — | 0 | — | ↗ |
| 2018-07-26 | Stewart Richard Alistair | Director / Officer | A-Award | A | Stock Option (right to buy) | 52,000 | 3.37 | 175.2K | 52,000 | — | ↗ |
| 2018-07-26 | JACOBS CINDY | Officer | A-Award | A | Stock Option (right to buy) | 20,000 | 3.37 | 67.4K | 20,000 | — | ↗ |
| 2018-07-26 | Clarke Anthony | Director / Officer | A-Award | A | Stock Option (right to buy) | 20,000 | 3.37 | 67.4K | 20,000 | — | ↗ |
| 2018-07-26 | Bencich John | Officer | A-Award | A | Stock Option (right to buy) | 25,000 | 3.37 | 84.3K | 25,000 | — | ↗ |
| 2017-10-10 | Cormack Scott Daniel | Director / Officer | M-Exempt | D | Restricted Stock Unit (RSU) | 3,125 | 0.00 | — | 3,125 | — | ↗ |
| 2017-09-08 | Cormack Scott Daniel | Director | F-InKind | D | Common Stock | 1,491 | 3.09 | 4.6K | 14,810 | — | ↗ |
| 2017-09-08 | Bencich John | Officer | M-Exempt | A | Common Stock | 454 | 0.00 | — | 1,507 | — | ↗ |
| 2017-08-01 | Stewart Richard Alistair | Director / Officer | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-08-01 | Schacter Robert | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,827,426 | — | ↗ |
| 2017-08-01 | PARKER H STEWART | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 4.57 | 50.3K | 11,000 | — | ↗ |
| 2017-08-01 | MOYES JAY M | Director | A-Award | A | Stock Option (right to buy) | 16,400 | 4.57 | 74.9K | 16,400 | — | ↗ |
| 2017-08-01 | MATTINGLY MARTIN A | Director | A-Award | A | Stock Option (right to buy) | 11,000 | 4.57 | 50.3K | 11,000 | — | ↗ |
| 2017-08-01 | Joseph Donald | Director | A-Award | A | Stock Option (right to buy) | 16,400 | 4.57 | 74.9K | 16,400 | — | ↗ |
| 2017-08-01 | JACOBS CINDY | Officer | A-Award | A | Restricted Stock Unit (RSU) | 54,800 | 0.00 | — | 54,800 | — | ↗ |
| 2017-08-01 | Cormack Scott Daniel | Director | M-Exempt | A | Common Stock | 1,590 | 0.00 | — | 9,685 | — | ↗ |
| 2017-08-01 | Clarke Anthony | Director / Officer | A-Award | A | Common Stock | 6,364,335 | 4.58 | 29.12M | 6,364,335 | — | ↗ |
| 2017-08-01 | Bencich John | Officer | A-Award | A | Stock Option (right to buy) | 274,000 | 2.89 | 791.9K | 274,000 | — | ↗ |
| 2017-06-12 | JACOBS CINDY | Officer | M-Exempt | A | Common Stock | 5,000 | 0.00 | — | 89,359 | — | ↗ |
| 2017-06-12 | Cormack Scott Daniel | Director / Officer | M-Exempt | A | Common Stock | 5,000 | 0.00 | — | 89,055 | — | ↗ |
| 2017-01-10 | JACOBS CINDY | Officer | F-InKind | D | Common Stock | 3,369 | 0.63 | 2.1K | 84,359 | — | ↗ |
Executive team
Top executives
Shares Outstanding
53.22M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Mark Oki, Chief Financial Officer John Bencich, | 473.1K | — | 796.3K | 258.0K | — | 991.6K | 2.52M | 41.85% | ↗ |
| 2 | 2023 | John Bencich, Chief Executive Officer | 530.0K | — | 490.0K | 426.2K | 251.8K | — | 1.70M | 53.96% | ↗ |
| 3 | 2023 | Mark Oki, Chief Financial Officer John Bencich, Former Chief Executive Officer | 530.0K | — | 490.0K | 426.2K | 251.8K | — | 1.70M | 53.96% | ↗ |
| 4 | 2023 | Richard Stewart, Chief Executive Officer | 450.0K | — | 367.5K | 319.7K | 213.8K | — | 1.35M | 50.87% | ↗ |
| 5 | 2023 | Richard Stewart, Executive Chairman | 450.0K | — | 367.5K | 319.7K | 213.8K | — | 1.35M | 50.87% | ↗ |
| 6 | 2023 | Cindy Jacobs, President and Chief Medical Officer | 473.0K | — | 294.0K | 255.7K | 179.7K | — | 1.20M | 45.72% | ↗ |
| 7 | 2022 | John Bencich, Chief Executive Officer | 510.0K | — | 413.0K | 358.7K | 223.1K | — | 1.50M | 51.28% | ↗ |
| 8 | 2022 | Richard Stewart, Executive Chairman | 400.0K | — | 371.7K | 322.8K | 175.0K | — | 1.27M | 54.71% | ↗ |
| 9 | 2022 | Cindy Jacobs, President and Chief Medical Officer | 455.0K | — | 268.5K | 233.1K | 159.3K | — | 1.12M | 44.95% | ↗ |
| 10 | 2021 | John Bencich, Chief Executive Officer | 465.0K | — | 196.4K | 648.3K | 302.3K | — | 1.61M | 52.40% | ↗ |
| 11 | 2021 | Richard Stewart, Executive Chairman | 400.0K | — | 130.9K | 540.2K | 260.0K | — | 1.33M | 50.42% | ↗ |
| 12 | 2021 | Cindy Jacobs, President and Chief Medical Officer | 440.0K | — | 65.5K | 324.1K | 228.8K | — | 1.06M | 36.81% | ↗ |
| 13 | 2020 | Richard Stewart, Executive Chairman and Former Chief Executive Officer | 473.8K | — | — | 333.0K | 225.6K | — | 1.03M | 32.25% | ↗ |
| 14 | 2020 | Richard Stewart, Executive Chairman | 473.8K | — | — | 333.0K | 225.6K | — | 1.03M | 32.25% | ↗ |
| 15 | 2020 | John Bencich, Chief Executive Officer and Former Chief Financial Officer and Chief Operating Officer | 420.9K | — | — | 263.2K | 199.6K | — | 883.7K | 29.78% | ↗ |
| 16 | 2020 | John Bencich, Chief Executive Officer | 420.9K | — | — | 263.2K | 199.6K | — | 883.7K | 29.78% | ↗ |
| 17 | 2020 | Cindy Jacobs, President and Chief Medical Officer | 420.2K | — | — | 194.1K | 159.6K | — | 773.9K | 25.08% | ↗ |
| 18 | 2019 | Richard Stewart, Executive Chairman | 500.0K | — | — | 109.1K | 187.5K | — | 796.6K | 13.70% | ↗ |
| 19 | 2019 | Richard Stewart, Executive Chairman and Former Chief Executive Officer | 500.0K | — | — | 109.1K | 187.5K | — | 796.6K | 13.70% | ↗ |
| 20 | 2019 | Richard Stewart, Chairman and Chief Executive Officer | 500.0K | — | — | 109.1K | 187.5K | — | 796.6K | 13.70% | ↗ |
| 21 | 2019 | Anthony Clarke, President and Chief Scientific Officer | 420.0K | — | — | 43.7K | 126.0K | — | 589.7K | 7.40% | ↗ |
| 22 | 2019 | Cindy Jacobs, President and Chief Medical Officer | 413.2K | — | — | 43.7K | 124.0K | — | 580.9K | 7.52% | ↗ |
| 23 | 2019 | Cindy Jacobs, Executive Vice President and Chief Medical Officer | 413.2K | — | — | 43.7K | 124.0K | — | 580.9K | 7.52% | ↗ |
| 24 | 2019 | John Bencich, Chief Executive Officer and Former Chief Financial Officer and Chief Operating Officer | 405.3K | — | — | 43.7K | 121.6K | — | 570.5K | 7.65% | ↗ |
| 25 | 2019 | John Bencich, Chief Executive Officer | 405.3K | — | — | 43.7K | 121.6K | — | 570.5K | 7.65% | ↗ |
| 26 | 2019 | John Bencich, Executive Vice President and Chief Financial Officer and Chief Operating Officer | 405.3K | — | — | 43.7K | 121.6K | — | 570.5K | 7.65% | ↗ |
| 27 | 2018 | Richard Stewart, Chairman and Chief Executive Officer | 500.0K | — | — | 317.6K | 272.6K | — | 1.09M | 29.13% | ↗ |
| 28 | 2018 | Richard Stewart, Executive Chairman and Former Chief Executive Officer | 500.0K | — | — | 317.6K | 272.6K | — | 1.09M | 29.13% | ↗ |
| 29 | 2018 | Anthony Clarke, President and Chief Scientific Officer | 420.0K | — | — | 118.7K | 183.2K | — | 721.9K | 16.44% | ↗ |
| 30 | 2018 | Cindy Jacobs, Executive Vice President and Chief Medical Officer | 413.2K | — | — | 118.7K | 180.3K | — | 712.2K | 16.67% | ↗ |
| 31 | 2018 | Cindy Jacobs, President and Chief Medical Officer | 413.2K | — | — | 118.7K | 180.3K | — | 712.2K | 16.67% | ↗ |
| 32 | 2018 | John Bencich, Executive Vice President and Chief Financial Officer and Chief Operating Officer | 375.5K | — | — | 155.4K | 163.8K | — | 694.7K | 22.37% | ↗ |
| 33 | 2018 | John Bencich, Chief Executive Officer and Former Chief Financial Officer and Chief Operating Officer | 375.5K | — | — | 155.4K | 163.8K | — | 694.7K | 22.37% | ↗ |
| 34 | 2017 | Cindy Jacobs, Executive Vice President and Chief Medical Officer | 413.2K | — | 158.4K | 574.7K | — | — | 1.15M | 63.95% | ↗ |
| 35 | 2017 | John Bencich, Executive Vice President and Chief Financial Officer and Chief Operating Officer | 335.8K | 75.0K | 158.4K | 574.7K | — | — | 1.14M | 64.08% | ↗ |
| 36 | 2017 | Scott Cormack, Former President and Chief Executive Officer | 317.9K | — | — | — | — | — | 317.9K | 0.00% | ↗ |
| 37 | 2017 | Richard Stewart, Chairman and Chief Executive Officer | 208.3K | — | — | — | — | — | 208.3K | 0.00% | ↗ |
| 38 | 2017 | Anthony Clarke, President and Chief Scientific Officer | 175.0K | — | — | — | — | — | 175.0K | 0.00% | ↗ |
| 39 | 2016 | Scott Cormack, Former President and Chief Executive Officer | 541.4K | — | — | 155.2K | — | — | 696.6K | 22.28% | ↗ |
| 40 | 2016 | Cindy Jacobs, Executive Vice President and Chief Medical Officer | 413.2K | — | — | 69.8K | — | — | 483.1K | 14.46% | ↗ |
| 41 | 2016 | John Bencich, Executive Vice President and Chief Financial Officer and Chief Operating Officer | 307.5K | — | — | 58.2K | — | — | 365.7K | 15.91% | ↗ |
| 42 | 2015 | Scott Cormack, Former President and Chief Executive Officer | 541.4K | — | 69.8K | 79.5K | 148.9K | — | 839.5K | 17.78% | ↗ |
| 43 | 2015 | Cindy Jacobs, Executive Vice President and Chief Medical Officer | 413.2K | — | 34.9K | 39.7K | 82.7K | — | 570.5K | 13.08% | ↗ |
| 44 | 2015 | John Bencich, Executive Vice President and Chief Financial Officer and Chief Operating Officer | 307.5K | — | 23.3K | 26.5K | 53.8K | — | 411.1K | 12.10% | ↗ |
| 45 | 2014 | Scott Cormack, Former President and Chief Executive Officer | 497.2K | — | 655.3K | 410.3K | 156.3K | — | 1.72M | 61.99% | ↗ |
| 46 | 2014 | Cindy Jacobs, Executive Vice President and Chief Medical Officer | 413.2K | — | 348.3K | 205.2K | 86.8K | — | 1.05M | 52.54% | ↗ |
| 47 | 2014 | John Bencich, Vice President and Chief Financial Officer | 118.3K | 20.0K | 63.4K | 93.3K | 18.5K | — | 313.5K | 49.99% | ↗ |
| 48 | 2014 | John Bencich, Executive Vice President and Chief Financial Officer and Chief Operating Officer | 118.3K | 20.0K | 63.4K | 93.3K | 18.5K | — | 313.5K | 49.99% | ↗ |
| 49 | 2013 | Scott Cormack, President and Chief Executive Officer | 503.7K | — | 553.0K | 324.1K | 207.8K | — | 1.59M | 55.21% | ↗ |
| 50 | 2013 | Cindy Jacobs, Executive Vice President and Chief Medical Officer | 403.1K | — | 338.8K | 172.8K | 120.9K | — | 1.04M | 49.40% | ↗ |
| 51 | 2013 | Michelle Burris, Former Executive Vice President Operations and Chief Financial Officer | 94.9K | — | 338.8K | 160.3K | 123.1K | 315.6K | 1.03M | 48.33% | ↗ |
| 52 | 2013 | Susan Wyrick, Principal Accounting Officer and Vice President, Finance | 200.0K | 5.0K | 109.2K | 77.7K | 40.0K | — | 431.9K | 43.27% | ↗ |
| 53 | 2012 | Scott Cormack, President and Chief Executive Officer | 520.4K | — | 487.5K | 374.1K | 257.6K | — | 1.64M | 52.55% | ↗ |
| 54 | 2012 | Cindy Jacobs, Executive Vice President and Chief Medical Officer | 391.4K | — | 268.1K | 149.7K | 140.9K | — | 950.1K | 43.97% | ↗ |
| 55 | 2012 | Michelle Burris, Former Executive Vice President Operations and Chief Financial Officer | 375.9K | — | 268.1K | 149.7K | 135.3K | — | 929.1K | 44.97% | ↗ |
| 56 | 2012 | Susan Wyrick, Principal Accounting Officer and Vice President, Finance | 107.9K | — | 62.9K | 56.1K | 43.0K | — | 269.9K | 44.08% | ↗ |
| 57 | 2012 | Cameron Lawrence, Former Principal Accounting Officer | 66.0K | — | — | 5.6K | 17.6K | 126.6K | 215.8K | 2.60% | ↗ |
| 58 | 2011 | Michelle Burris, Former Executive Vice President Operations and Chief Financial Officer | 365.0K | — | — | 417.6K | 95.8K | — | 878.4K | 47.54% | ↗ |
| 59 | 2011 | Michelle Burris, Executive Vice President Operations and Chief Financial Officer | 365.0K | — | — | — | 95.8K | — | 878.4K | 0.00% | ↗ |
| 60 | 2011 | Scott Cormack, President and Chief Executive Officer | 499.5K | — | — | — | 183.9K | — | 683.3K | 0.00% | ↗ |
| 61 | 2011 | Cindy Jacobs, Executive Vice President and Chief Medical Officer | 380.0K | — | — | — | 99.8K | — | 479.8K | 0.00% | ↗ |
| 62 | 2011 | Cameron Lawrence, Former Principal Accounting Officer | 138.0K | — | — | — | 17.1K | — | 155.1K | 0.00% | ↗ |
| 63 | 2011 | Susan Wyrick, Principal Accounting Officer and Vice President, Finance | — | — | — | — | — | — | — | — | ↗ |
| 64 | 2010 | Scott Cormack, President and Chief Executive Officer | 475.8K | — | — | 453.6K | 214.1K | — | 1.14M | 39.67% | ↗ |
| 65 | 2010 | Cindy Jacobs, Executive Vice President and Chief Medical Officer | 369.0K | — | — | 226.8K | 116.5K | — | 712.3K | 31.84% | ↗ |
| 66 | 2010 | Cindy Jacobs, Executive Vice President and Chief Medical Officer | 369.0K | — | — | 226.8K | — | — | 712.3K | 31.84% | ↗ |
| 67 | 2010 | Stephen Anderson, Former Chief Financial Officer | 39.9K | — | — | — | — | — | 221.8K | 0.00% | ↗ |
| 68 | 2010 | Cameron Lawrence, Former Principal Accounting Officer | 98.1K | 17.5K | — | 45.4K | 16.5K | — | 177.4K | 25.57% | ↗ |
| 69 | 2009 | Scott Cormack, President and Chief Executive Officer | 302.6K | — | — | 392.3K | — | — | 816.0K | 48.08% | ↗ |
| 70 | 2009 | Scott Cormack, President, Chief | 302.6K | — | — | 392.3K | 121.1K | — | 816.0K | 48.08% | ↗ |
| 71 | 2009 | Cindy Jacobs, Executive Vice | 360.0K | — | — | 188.3K | 108.0K | — | 656.3K | 28.69% | ↗ |
| 72 | 2009 | Cindy Jacobs, Executive Vice President and Chief Medical Officer | 360.0K | — | — | 188.3K | — | — | 656.3K | 28.69% | ↗ |
| 73 | 2009 | Stephen Anderson, Former Chief Financial Officer | 184.2K | — | — | 125.5K | — | — | 355.8K | 35.28% | ↗ |
| 74 | 2009 | Stephen Anderson, Former Chief | 184.2K | — | — | 125.5K | 46.1K | — | 355.8K | 35.28% | ↗ |
| 75 | 2009 | Michael Martino, Former President and Chief Executive | — | — | — | — | — | — | — | — | ↗ |
| 76 | 2009 | Alan Fuhrman, Former Senior Vice President and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 77 | 2008 | Michael A. Martino, Former President and Chief Executive Officer; Director | 251.4K | — | — | 240.2K | — | 1.14M | 1.63M | 14.74% | ↗ |
| 78 | 2008 | Michael Martino, Former President and Chief Executive | 251.4K | — | — | 115.3K | — | 1.14M | 1.50M | 7.66% | ↗ |
| 79 | 2008 | Alan Fuhrman, Former Senior Vice President and Chief | 170.9K | — | — | 133.3K | — | 262.0K | 566.3K | 23.54% | ↗ |
| 80 | 2008 | Alan Fuhrman, Former Senior Vice President and Chief Financial Officer | 170.9K | — | — | 74.6K | — | 262.0K | 507.5K | 14.69% | ↗ |
| 81 | 2008 | Scott Cormack, President, Chief | 97.9K | — | — | 194.7K | 183.9K | — | 476.4K | 40.86% | ↗ |
| 82 | 2008 | Scott Cormack, President and Chief Executive Officer | 97.9K | — | — | 194.7K | — | — | 476.4K | 40.86% | ↗ |
| 83 | 2008 | Cindy Jacobs, Executive Vice | 127.6K | — | — | 77.9K | 182.0K | — | 387.5K | 20.10% | ↗ |
| 84 | 2008 | Cindy Jacobs, Executive Vice President and Chief Medical Officer | 127.6K | — | — | 77.9K | — | — | 387.5K | 20.10% | ↗ |
| 85 | 2008 | Cindy Jacobs, Executive Vice President and Chief Medical Officer | 127.6K | — | — | 2.4K | 182.0K | — | 312.0K | 0.77% | ↗ |
| 86 | 2008 | Stephen Anderson, Former Chief | 60.6K | — | — | 136.3K | 70.2K | — | 267.1K | 51.03% | ↗ |
| 87 | 2008 | Stephen Anderson, Former Chief Financial Officer | 60.6K | — | — | 136.3K | — | — | 267.1K | 51.03% | ↗ |
| 88 | 2007 | Michael A. Martino, Former President and Chief Executive Officer; Director | 376.4K | — | — | 338.1K | — | 12.3K | 726.8K | 46.52% | ↗ |
| 89 | 2007 | Alan Fuhrman, Former Senior Vice President and Chief | 255.9K | — | — | 184.1K | — | 7.5K | 447.5K | 41.14% | ↗ |
| 90 | 2007 | Michael Martino, Former President and Chief Executive | 376.4K | — | — | — | — | 12.3K | 388.7K | 0.00% | ↗ |
| 91 | 2007 | Alan Fuhrman, Former Senior Vice President and Chief Financial Officer | 255.9K | — | — | — | — | 7.5K | 263.4K | 0.00% | ↗ |
| 92 | 2006 | Michael A. Martino President, Chief Executive Officer and Director Senior Vice President, Vice President, Finance and Chief Financial Officer Vice President, Clinical and Regulatory Affairs | 374.0K | — | — | 367.5K | 175.0K | 15.5K | 932.0K | 39.43% | ↗ |
| 93 | 2006 | Michael A. Martino, Former President and Chief Executive Officer; Director | 374.0K | — | — | 222.2K | 175.0K | 15.5K | 786.8K | 28.25% | ↗ |
| 94 | 2006 | Michael B. Stewart, M.D. | 137.7K | — | — | 290.8K | — | 158.4K | 586.9K | 49.55% | ↗ |
| 95 | 2006 | Alan Fuhrman, Former Senior Vice President and Chief | 245.7K | — | — | 137.8K | 94.9K | 8.4K | 486.8K | 28.30% | ↗ |
| 96 | 2006 | Alan Fuhrman Senior Vice President and Chief Financial Officer | 245.7K | — | — | 122.2K | 94.9K | 8.4K | 471.3K | 25.94% | ↗ |
| 97 | 2005 | Michael A. Martino President, Chief Executive Officer and Director | 345.8K | 233.8K | — | — | — | 7.5K | 579.6K | 0.00% | ↗ |
| 98 | 2005 | Michael B. Stewart, M.D. Senior Vice President and Chief Medical Officer | 261.1K | 114.4K | — | — | — | 4.3K | 375.5K | 0.00% | ↗ |
| 99 | 2005 | Alan Fuhrman Senior Vice President and Chief Financial Officer | 220.0K | 96.3K | — | — | — | 1.2K | 316.3K | 0.00% | ↗ |
| 100 | 2004 | Michael A. Martino President, Chief Executive Officer and Director | 333.0K | 107.6K | — | — | — | 9.4K | 441.0K | 0.00% | ↗ |
| 101 | 2004 | Michael B. Stewart, M.D. Senior Vice President and Chief Medical Officer | 251.5K | 63.2K | — | — | — | 1.1K | 314.7K | 0.00% | ↗ |
| 102 | 2004 | Michael B. Stewart, M.D. Senior Vice President and Chief | 251.5K | 63.2K | — | — | — | 1.1K | 314.7K | 0.00% | ↗ |
| 103 | 2004 | Richard J. Klein Senior Vice President and Chief Financial Officer | 142.3K | — | — | — | — | 1.6K | 142.3K | 0.00% | ↗ |
| 104 | 2004 | Alan Fuhrman Senior Vice President and Chief Financial Officer | 55.9K | 18.7K | — | — | — | — | 74.5K | 0.00% | ↗ |
| 105 | 2003 | Michael A. Martino President, Chief Executive Officer and Director | 305.0K | 125.7K | — | — | — | 10.1K | 430.7K | 0.00% | ↗ |
| 106 | 2003 | Michael B. Stewart, M.D. Senior Vice President and Chief Medical Officer | 212.7K | 79.7K | — | — | — | 700.00 | 292.4K | 0.00% | ↗ |
| 107 | 2003 | Michael B. Stewart, M.D. Senior Vice President and Chief | 212.7K | 79.7K | — | — | — | 700.00 | 292.4K | 0.00% | ↗ |
| 108 | 2003 | Richard J. Klein Senior Vice President and Chief Financial Officer | 205.0K | 52.4K | — | — | — | 4.9K | 257.4K | 0.00% | ↗ |
| 109 | 2002 | Michael A. Martino President, Chief Executive Officer and Director Senior Vice President, Vice President, Finance and Chief Financial Officer Vice President, Clinical and Regulatory Affairs | 275.0K | 86.5K | — | — | — | — | 361.5K | 0.00% | ↗ |
| 110 | 2002 | Michael A. Martino President, Chief Executive Officer and Director | 275.0K | 86.5K | — | — | — | 13.2K | 361.5K | 0.00% | ↗ |
| 111 | 2002 | Senior Vice President and Chief Financial Officer Michael B. Stewart, M.D. Senior Vice President and Chief Medical Officer | 180.0K | 37.1K | — | — | — | — | 217.1K | 0.00% | ↗ |
| 112 | 2002 | Richard J. Klein Senior Vice President and Chief Financial Officer | 180.0K | 37.1K | — | — | — | 7.4K | 217.1K | 0.00% | ↗ |
| 113 | 2001 | Michael A. Martino President, Chief Executive Officer and Director | 250.0K | 426.5K | — | — | — | — | 676.5K | 0.00% | ↗ |
| 114 | 2001 | Michael A. Martino President, Chief Executive Officer and Vice President, Finance and Chief Financial Officer Vice President, Clinical and Regulatory Affairs | 250.0K | 426.5K | — | — | — | — | 676.5K | 0.00% | ↗ |
| 115 | 2001 | Michael A. Martino President, Chief Executive Officer and Director Senior Vice President, Vice President, Finance and Chief Financial Officer Vice President, Clinical and Regulatory Affairs | 250.0K | 426.5K | — | — | — | — | 676.5K | 0.00% | ↗ |
| 116 | 2001 | Senior Vice President and Chief Financial Officer Michael B. Stewart, M.D. Senior Vice President and Chief Medical Officer | 165.0K | 194.5K | — | — | — | — | 359.5K | 0.00% | ↗ |
| 117 | 2000 | Michael A. Martino President, Chief Executive Officer and Vice President, Finance and Chief Financial Officer Vice President, Clinical and Regulatory Affairs | 250.0K | — | — | — | — | — | 250.0K | 0.00% | ↗ |
| 118 | 2000 | Michael A. Martino President, Chief Executive Officer and Director Senior Vice President, Vice President, Finance and Chief Financial Officer Vice President, Clinical and Regulatory Affairs | 250.0K | — | — | — | — | — | 250.0K | 0.00% | ↗ |
| 119 | 1999 | Michael A. Martino President, Chief Executive Officer and Vice President, Finance and Chief Financial Officer Vice President, Clinical and Regulatory Affairs | 250.0K | — | — | — | — | — | 250.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
| Filing date | Form type | Filing |
|---|---|---|
| 2025-04-28 | DEF 14A | ↗ |
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Richard A. Stewart | President, CEO & Executive Director | 892.1K | — |
| Andrew D. Goldberg | Chief Executive Officer & Director | 781.8K | — |
| Jaime Xinos | Chief Commercial Officer | 585.0K | female |
| Erik Atkisson | Chief Legal Officer | 521.0K | male |
| Mark K. Oki | Chief Financial Officer | 425.2K | male |
| Jerry Wan | Vice President of Finance & Principal Accounting Officer | — | male |
| Mark L. Rubinstein | Chief Medical Officer | — | — |
| Nicole Jones | Vice President of Strategic Communications & Stakeholder Relations | — | female |
| Craig Donnelly | Chief Operations Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ACHV
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
